Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 15:27:08 GMT -5
I believe it is but if was not, MannKind could reduce the price to gain greater scripts.
|
|
|
|
Post by bill on Jan 6, 2016 15:33:41 GMT -5
I agree for anything that SNY sells. However, MNKD can offer Afrezza on their own now and keep the revenue since SNY's exclusivity is no more. Not sure how that gets handled logistically, though.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 15:52:53 GMT -5
I think there needs to be more questions asked then just that. I would think that since the loan agreement is still in place until 7/4 which is the conclusion of the notice period the revenue sharing would remain the same also
Here are my questions
1) Can we start to sell Afrezza today without SNY or do we need to wait until 7/4 (although many are claiming this it is not clear)
2) If we can how are new sales being differentiated? Meaning are SNY targeted Dr's writing new scripts falling under the 65/35 or is it now MNKDs 100%
|
|
|
|
Post by kc on Jan 6, 2016 15:54:34 GMT -5
I agree for anything that SNY sells. However, MNKD can offer Afrezza on their own now and keep the revenue since SNY's exclusivity is no more. Not sure how that gets handled logistically, though. Do we have the ability to have branded packages? I think that Sanofi was taking product and packaging it elsewhere? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 16:23:53 GMT -5
Can price be reduced to be competitive with pens?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 17:10:07 GMT -5
My email to Matt:
Is the 65/35 split still in effect? Can MannKind reduce the price of Afrezza before July? Need an Afrezza sales rep in Chicago area?
Matt's reply:
Yes, yes and maybe...
|
|
|
|
Post by doublebogey on Jan 6, 2016 19:37:19 GMT -5
Ability to reduce the price is great news. I just have this feeling that SNY priced Afrezza too much to account for their profit and MNKD's 35% share of that profit. If Afrezza can be sold at around $3/day and MNKD is profitable in the price range we might get some head way in the insurance coverage to Tier 2.
|
|
|
|
Post by saxcmann on Jan 6, 2016 20:03:25 GMT -5
My email to Matt: Is the 65/35 split still in effect? Can MannKind reduce the price of Afrezza before July? Need an Afrezza sales rep in Chicago area? Matt's reply: Yes, yes and maybe... I can sell Afrezza in North Carolina. I guarantee I could sell more than Sanofi did! Tell Matt...I have a great reference. I heard Sanofi reps weren't even pushing afrezza unless a endo was already selling it. What a joke! |
|
|
|
Post by sluggobear on Jan 6, 2016 20:54:36 GMT -5
They will have to put employees on hiatus or let them go. They could move 25-50 of them to sales (if qualified) and let them have a go at selling Afrezza for small base and commission.
|
|
|
|
Post by nylefty on Jan 6, 2016 21:01:51 GMT -5
My email to Matt: Is the 65/35 split still in effect? Can MannKind reduce the price of Afrezza before July? Need an Afrezza sales rep in Chicago area? Matt's reply: Yes, yes and maybe... So MannKind "may" be hiring Afrezza sales reps? That's news! |
|
|
|
Post by dictatorsaurus on Jan 6, 2016 21:13:24 GMT -5
I'm an Engineer and work in generics.
Willing to work as an Afrezza sales rep on the weekends.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 6, 2016 21:29:10 GMT -5
I'm an Engineer and work in generics. Willing to work as an Afrezza sales rep on the weekends. docs open on weekend's? I am happy to serve tea/coffee/lunch to DeSisto and Matt and Al while they spend their energy in getting out of this obstacle |
|
|
|
Post by dictatorsaurus on Jan 6, 2016 21:37:43 GMT -5
I'm an Engineer and work in generics. Willing to work as an Afrezza sales rep on the weekends. docs open on weekend's? I am happy to serve tea/coffee/lunch to DeSisto and Matt and Al while they spend their energy in getting out of this obstacle Yes some do. At least here in NJ. |
|
|
|
Post by seanismorris on Jan 6, 2016 22:26:06 GMT -5
Increasing scripts is more important than not losing a bit more money for the next few months.
Increase scripts and everyone will be willing to loaning them money (and on good terms). The bleeding of cash would have an end in sight.
If that happened, even with dilution, I'd be a buyer of MNKD shares.
|
|
|
|
Post by dreamboatcruise on Jan 6, 2016 22:30:44 GMT -5
While MannKind can reduce the price before the partnership ends, doing so would probably end up costing MannKind $ by selling below cost. I was hoping that the 65/35 ended in order to reduce price. MNKD would still get 100% of production costs before SNY got any split of the revenue. It is a bit surprising that MNKD has the ability to change the pricing while the profit share is still in place, but perhaps this was something they negotiated after SNY announced the deal cancellation. I suppose SNY doesn't have a heck of a lot to lose in letting them lower the price at this point... the additional financial loss to SNY would be drop in bucket compared to write off already in the works for them. |
|
